Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 5 - The Untold Story

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Tylenol maker prepares for glut of lawsuits after Trump’s baseless warnings

Tylenol maker prepares for glut of lawsuits after Trump’s baseless warnings

‘Don’t take Tylenol,’ President Donald Trump repeatedly warned on Monday

The Independent UK

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors

Johnson Johnson (NYSE:JNJ) is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux.

What Is the 'Tylenol Murders' and Why Does the Famous Analgesic Keep Getting Linked to Controversies?

More than 40 years after the unexpected deaths of seven people due to tainted medicine, Tylenol became the centre of attention again for a different reason.

International Business Times UK

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

3 Dividend Stocks to Hold Through Market Volatility This Fall

3 Dividend Stocks to Hold Through Market Volatility This Fall

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery

Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst

Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

Get all your
news in one place.

100's of premium titles.
One news app.

How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?

Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Bridgewater, Once Led By Ray Dalio, Exits Alibaba, JD, PDD And Baidu, Dumping All US-listed Chinese Stocks Amid Geopolitical Risks

Bridgewater Associates, the world's largest hedge fund, has completely liquidated its holdings in all U.S.-listed Chinese companies, a dramatic reversal that marks the firm's most significant strategic pivot under its new post-Ray Dalio leadership.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Dividend Growth Leaders to Buy Now

Procter & Gamble, PepsiCo, and Johnson & Johnson stand out as dividend growth leaders with upside potential into year-end

JNJ Stock Surge Signals Confidence in New Growth Path

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.

The Independent UK

India police bust racket of fake life-saving drugs under label of top brands

The counterfeit drug ring operated through an extensive network spanning multiple Indian states

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.

1 … 4 5 6 7

People

194,199 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Wikimedia Commons

Johnson & Johnson (

UnitedHealth Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

146,087 stories

Rheumatoid Arthritis

Places

382,341 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play